Last reviewed · How we verify
Butyn (BUTACAINE)
At a glance
| Generic name | BUTACAINE |
|---|---|
| Drug class | butacaine |
| Target | Sodium channel alpha subunits; brain (Types I, II, III) |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Bladder muscle dysfunction - overactive
- Increased Urinary Frequency
- Neurogenic bladder
- Urge incontinence of urine
- Urgent desire to urinate
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Butyn CI brief — competitive landscape report
- Butyn updates RSS · CI watch RSS